For the quarter ending 2026-03-31, TRAX had $10,273K increase in cash & cash equivalents over the period. -$32,578K in free cash flow.
| Cash Flow | 2026-03-31 |
|---|---|
| Net loss | -50,484 |
| Depreciation and amortization | 125 |
| Stock-based compensation | 11,503 |
| Accretion/amortization of investments, net | 8 |
| Amortization of right-of-use assets - operating | 0 |
| Prepaid expenses and other assets | -2,157 |
| Accounts payable and other liabilities | 4,146 |
| Operating lease liabilities | 0 |
| Net cash used in operating activities | -32,561 |
| Purchase of investments | 0 |
| Sales and maturities of investments | 35,000 |
| Purchases of property and equipment | 17 |
| Net cash provided by investing activities | 34,983 |
| Net parent investment | -7,851 |
| Net cash provided by financing activities | 7,851 |
| Net increase (decrease) in cash and cash equivalents | 10,273 |
| Cash and cash equivalents, beginning of period | 238,196 |
| Cash and cash equivalents, end of period | 248,469 |
First Tracks Biotherapeutics, Inc. (TRAX)
First Tracks Biotherapeutics, Inc. (TRAX)